About G-protein coupled receptor 176
G-protein coupled receptor 176 (GPR176) is a protein
from Homo sapiens identified by UniProt accession
Q14439, 515 residues long.
MolForge cross-references it against 0 known binders and
53 disease associations.
Target properties
| Protein name | G-protein coupled receptor 176 |
| UniProt accession | Q14439 |
| Gene | GPR176 |
| Organism | Homo sapiens |
| Length | 515 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (53)
Diseases linked to this target (Open Targets).
- body height · score 0.32
- gut microbiome measurement · score 0.30
- gonorrhea · score 0.09
- gastric adenocarcinoma · score 0.08
- neoplasm · score 0.07
- breast cancer · score 0.07
- cortical thickness · score 0.06
- congenital secretory chloride diarrhea 1 · score 0.05
- brain volume measurement · score 0.05
- brain measurement · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q14439-F1 | alphafold | PREDICTED | 66.46 | — |
Amino-acid sequence (515 residues)
MGHNGSWISP NASEPHNASG AEAAGVNRSA LGEFGEAQLY RQFTTTVQVV IFIGSLLGNF MVLWSTCRTT VFKSVTNRFI KNLACSGICA SLVCVPFDII LSTSPHCCWW IYTMLFCKVV KFLHKVFCSV TILSFPAIAL DRYYSVLYPL ERKISDAKSR ELVMYIWAHA VVASVPVFAV TNVADIYATS TCTEVWSNSL GHLVYVLVYN ITTVIVPVVV VFLFLILIRR ALSASQKKKV IIAALRTPQN TISIPYASQR EAELHATLLS MVMVFILCSV PYATLVVYQT VLNVPDTSVF LLLTAVWLPK VSLLANPVLF LTVNKSVRKC LIGTLVQLHH RYSRRNVVST GSGMAEASLE PSIRSGSQLL EMFHIGQQQI FKPTEDEEES EAKYIGSADF QAKEIFSTCL EGEQGPQFAP SAPPLSTVDS VSQVAPAAPV EPETFPDKYS LQFGFGPFEL PPQWLSETRN SKKRLLPPLG NTPEELIQTK VPKVGRVERK MSRNNKVSIF PKVDS
Explore G-protein coupled receptor 176 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets